Difference between revisions of "Template:Antithrombotics"
Jump to navigation
Jump to search
blackwiki>Ronhjones (use listclass = hlist in navbox as per WP:HLIST) |
m (131 revisions imported) |
||
| (30 intermediate revisions by 21 users not shown) | |||
| Line 1: | Line 1: | ||
{{Navbox | {{Navbox | ||
| − | | name | + | | name = Antithrombotics |
| − | | title = [[Antithrombotic]]s ([[ | + | | title = [[Antithrombotic]]s ([[Thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) |
| − | + | | state = {{{state<includeonly>|autocollapse</includeonly>}}} | |
| − | + | | bodyclass = hlist | |
| − | | | ||
| − | | group1 = [[Antiplatelet drug]]s | + | | group1 = [[Antiplatelet drug]]s |
| − | | | + | | list1 = {{Navbox|child |
| − | |||
| − | | group1 = [[Glycoprotein IIb/IIIa inhibitors]] | + | | group1 = [[Glycoprotein IIb/IIIa inhibitors]] |
| − | | | + | | list1 = |
* [[Abciximab]] | * [[Abciximab]] | ||
* [[Eptifibatide]] | * [[Eptifibatide]] | ||
| + | * [[Orbofiban]] | ||
| + | * [[Roxifiban]] | ||
| + | * [[Sibrafiban]]<sup>§</sup> | ||
* [[Tirofiban]] | * [[Tirofiban]] | ||
| − | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | + | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] |
| − | | | + | | list2 = |
| − | * | + | * [[Thienopyridine]]s |
| − | * [[Prasugrel]] | + | ** [[Clopidogrel]] |
| − | * [[Ticlopidine]] | + | ** [[Prasugrel]] |
| − | * | + | ** [[Ticlopidine]] |
| − | * [[Elinogrel]] | + | * [[Nucleotide]]/[[nucleoside]] analogs |
| − | * [[Ticagrelor]] | + | ** [[Cangrelor]] |
| + | ** [[Elinogrel]] | ||
| + | ** [[Ticagrelor]] | ||
| − | | group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | + | | group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) |
| − | | | + | | list3 = |
* [[Beraprost]] | * [[Beraprost]] | ||
| + | * [[Iloprost]] | ||
* [[Prostacyclin]] | * [[Prostacyclin]] | ||
| − | |||
* [[Treprostinil]] | * [[Treprostinil]] | ||
| − | | group4 = [[Mechanism of action of aspirin|COX inhibitors]] | + | | group4 = [[Mechanism of action of aspirin|COX inhibitors]] |
| − | | | + | | list4 = |
* [[Aspirin|Acetylsalicylic acid/Aspirin]]<sup>#</sup> | * [[Aspirin|Acetylsalicylic acid/Aspirin]]<sup>#</sup> | ||
* [[Aloxiprin]] | * [[Aloxiprin]] | ||
| Line 40: | Line 43: | ||
* [[Triflusal]] | * [[Triflusal]] | ||
| − | | group5 = [[Thromboxane inhibitors]] | + | | group5 = [[Thromboxane inhibitors]] |
| − | | | + | | list5 = |
| − | * | + | * [[Thromboxane synthase inhibitors]] |
| − | * [[Picotamide]] | + | ** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+ aspirin]]) |
| − | * | + | ** [[Picotamide]] |
| + | ** [[Terbogrel]] | ||
| + | * [[Thromboxane receptor antagonist|Receptor antagonist]]s | ||
| + | ** [[Terbogrel]] | ||
| + | ** [[Terutroban]]<sup>§</sup> | ||
| − | | group6 = [[Phosphodiesterase inhibitor]]s | + | | group6 = [[Phosphodiesterase inhibitor]]s |
| − | | | + | | list6 = |
* [[Cilostazol]] | * [[Cilostazol]] | ||
* [[Dipyridamole]] | * [[Dipyridamole]] | ||
* [[Triflusal]] | * [[Triflusal]] | ||
| − | | group7 = Other | + | | group7 = Other |
| − | | | + | | list7 = |
* [[Cloricromen]] | * [[Cloricromen]] | ||
* [[Ditazole]] | * [[Ditazole]] | ||
| + | * [[Vorapaxar]] | ||
| − | }} | + | }} |
| − | | group2 = [[Anticoagulant]]s | + | | group2 = [[Anticoagulant]]s |
| − | | | + | | list2 = {{Navbox|child |
| − | + | | evenodd = swap | |
| − | + | | group1 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) | |
| − | + | | list1 = | |
| − | * | + | * [[Coumarin]]s: [[Acenocoumarol]] |
* [[Coumatetralyl]] | * [[Coumatetralyl]] | ||
* [[Dicoumarol]] | * [[Dicoumarol]] | ||
| Line 71: | Line 79: | ||
* [[Phenprocoumon]] | * [[Phenprocoumon]] | ||
* [[Warfarin]]<sup>#</sup> | * [[Warfarin]]<sup>#</sup> | ||
| − | + | * [[1,3-Indandione]]s: [[Clorindione]] | |
| − | * | ||
* [[Diphenadione]] | * [[Diphenadione]] | ||
* [[Phenindione]] | * [[Phenindione]] | ||
| + | * Other: [[Tioclomarol]] | ||
| − | + | | group2 = [[Factor Xa]] inhibitors<br />(with some II inhibition) | |
| + | | list2 = {{Navbox|child | ||
| − | | | + | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) |
| − | | | + | | list1 = |
| − | + | * [[Low-molecular-weight heparin]] | |
| + | ** [[Bemiparin sodium|Bemiparin]] | ||
| + | ** [[Certoparin sodium|Certoparin]] | ||
| + | ** [[Dalteparin sodium|Dalteparin]] | ||
| + | ** [[Enoxaparin sodium|Enoxaparin]] | ||
| + | ** [[Nadroparin calcium|Nadroparin]] | ||
| + | ** [[Parnaparin sodium|Parnaparin]] | ||
| + | ** [[Reviparin sodium|Reviparin]] | ||
| + | ** [[Tinzaparin sodium|Tinzaparin]] | ||
| + | * [[Oligosaccharide]]s | ||
| + | ** [[Fondaparinux]] | ||
| + | ** [[Idraparinux]]<sup>§</sup> | ||
| + | * [[Heparinoid]]s | ||
| + | ** [[Danaparoid]] | ||
| + | ** [[Dermatan sulfate]] | ||
| + | ** [[Sulodexide]] | ||
| − | | | + | | group2 = [[Direct Xa inhibitor]]s ("xabans") |
| − | + | | list2 = | |
| − | + | * [[Apixaban]] | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | | | ||
| − | * | ||
* [[Betrixaban]] | * [[Betrixaban]] | ||
| + | * [[Darexaban]]<sup>§</sup> | ||
* [[Edoxaban]] | * [[Edoxaban]] | ||
| − | * [[Otamixaban]] | + | * [[Otamixaban]]<sup>§</sup> |
| − | * [[Rivaroxaban]] | + | * [[Rivaroxaban]] |
| − | }} | + | }} |
| − | + | <!-- group3 omitted to preserve alternating striping --> | |
| − | |||
| − | |||
| − | |||
| − | |||
| − | * | + | | group4 = [[Direct thrombin inhibitor|Direct thrombin (IIa) inhibitor]]s |
| + | | list4 = | ||
| + | * [[Direct thrombin inhibitor#Bivalent|Bivalent]]: [[Hirudin]] | ||
| + | ** [[Bivalirudin]] | ||
| + | ** [[Desirudin]] | ||
| + | ** [[Lepirudin]] | ||
| + | * [[Direct thrombin inhibitor#Univalent|Univalent]]: [[Argatroban]] | ||
* [[Dabigatran]] | * [[Dabigatran]] | ||
| + | * [[Efegatran]] | ||
| + | * [[Inogatran]]<sup>§</sup> | ||
* [[Melagatran]]<sup>‡</sup> | * [[Melagatran]]<sup>‡</sup> | ||
* [[Ximelagatran]]<sup>‡</sup> | * [[Ximelagatran]]<sup>‡</sup> | ||
| − | | | + | | group5 = Other |
| − | | | + | | list5 = |
| − | * [[ | + | * [[Antithrombin|Antithrombin III]] |
* [[Defibrotide]] | * [[Defibrotide]] | ||
| + | * [[Protein C]] | ||
| + | ** [[Drotrecogin alfa]]<sup>‡</sup> | ||
* [[Ramatroban]] | * [[Ramatroban]] | ||
| − | * [[ | + | * [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] |
| − | |||
| − | }} | + | }} |
| − | | | + | | group3 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s |
| − | | | + | | list3 = |
| − | * | + | * [[Plasminogen activator]]s: [[Recombinant tissue plasminogen activators|r-tPA]] |
| − | * [[Reteplase]] | + | ** [[Alteplase]] |
| − | * [[Tenecteplase]] | + | ** [[Reteplase]] |
| − | * | + | ** [[Tenecteplase]] |
| − | * [[Saruplase]] | + | ** [[Desmoteplase]]<sup>†</sup> |
| − | * [[ | + | * UPA |
| + | ** [[Saruplase]] | ||
| + | ** [[Urokinase]] | ||
* [[Anistreplase]] | * [[Anistreplase]] | ||
* [[Monteplase]] | * [[Monteplase]] | ||
| − | + | * [[Streptokinase]]<sup>#</sup> | |
| − | * | + | * Other [[serine endopeptidase]]s: [[Ancrod]] |
| + | * [[Brinase]] | ||
* [[Fibrinolysin]] | * [[Fibrinolysin]] | ||
| − | |||
| − | |||
| − | | | + | | group4 = [[Anticoagulant|Non-medicinal]] |
| − | | | + | | list4 = |
* [[Citrate]] | * [[Citrate]] | ||
| − | * [[EDTA]] | + | * [[Ethylenediaminetetraacetic acid|EDTA]] |
* [[Oxalate]] | * [[Oxalate]] | ||
| − | + | | belowstyle = background: transparent; padding: 0px; | |
| − | + | | below = {{PharmNavFootnote}} | |
| − | |||
| − | | belowstyle = background: transparent; padding: 0px; | ||
| − | | below = {{PharmNavFootnote | ||
}}<noinclude> | }}<noinclude> | ||
| − | + | {{collapsible option}} | |
| − | [[Category: | + | [[Category:Drug templates by ATC]] |
| − | |||
| − | |||
| − | |||
</noinclude> | </noinclude> | ||
Latest revision as of 14:27, 22 October 2020
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Antithrombotics|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Antithrombotics|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Antithrombotics|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.